RxDoctor Payments DataLook up a doctor →

Carmine Oddis, MD

Nuclear Radiology · Macon, GANPI 1659315737

Payments from drug & device makers

$42,402in general payments, 2019–2025

Across 579 payments — averaging $73.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$32K
  • Novartis$2K
  • Pfizer$1K
  • Medtronic$1K
  • Johnson & Johnson$1K
  • Actelion Pharmaceuticals US, Inc.$540
  • plus $4K from 24 others

What the payments were for

  • Consulting fees$1,2887%
  • Travel & lodging$3,84422%
  • Food & beverage$12,52871%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear radiology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,145,522
Medicare patients
2,381
Services billed
13,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,672$1,459,572
XareltoRivaroxaban585$494,362
EntrestoSacubitril/Valsartan392$378,563
OpsumitMacitentan14$172,877
FarxigaDapagliflozin Propanediol104$71,716
Flecainide Acetate1,453$56,145
Repatha SureclickEvolocumab45$35,358
MultaqDronedarone Hcl28$23,640
Propafenone Hcl371$21,666
Pyridostigmine Bromide630$16,016
Amiodarone Hcl792$13,833
Midodrine Hcl291$12,716
Propafenone Hcl ErPropafenone Hcl52$10,840
Dofetilide95$10,560
JardianceEmpagliflozin11$9,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,418$1,459,5721,672 claims
Johnson & JohnsonXarelto$1,098$494,362585 claims
NovartisEntresto$2,022$378,563392 claims
Actelion Pharmaceuticals US, Inc.Opsumit$540$172,87714 claims
AstraZenecaFarxiga$476$71,716104 claims
Sanofi-aventis U.S. LLCMultaq$158$23,64028 claims
Boehringer IngelheimJardiance, Pradaxa$149$18,35041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear radiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other nuclear radiology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →